top of page

A Therapeutic Pipeline
to expand the impact of our mission

SDT is a Platform Technology

SonALAsense is pursuing a pipeline of additional indications utilizing SDT to treat multiple tumor types.

While our initial focus is on aggressive brain tumors and our secondary focus is on tumors outside the brain, SONALA-001 in combination with MR-guided focused ultrasound has the potential to treat the majority of tumors of epithelial origin: gliomas, meningiomas, pancreatic, ovarian, gastric, bladder, skin, esophageal, lung, gall bladder, and breast cancer.


SONALA-001 in Combination with the Exablate 2.0 Device

SonALAsense is the first company to advance sonodynamic therapy into clinical trials.

Phase 0/1 Recurrent High-Grade Glioma, rHGG

Phase 1/2 Diffuse Intrinsic Pontine Glioma, DIPG (SDT-201)

Phase 2 Recurrent Glioblastoma, rGBM (SDT-202)

SONALA-001 in Combination with a Body System

bottom of page